Big Pharma Split Corp Class A (PRM) — Capital Reinvestment Ratio
Big Pharma Split Corp Class A (PRM) has a Capital Reinvestment Ratio of 0.00x as of December 2023, meaning it reinvests 0% of its operating cash flow (CA$11.86 Million) in capital expenditures (CA$3.00). Check Big Pharma Split Corp Class A tangible book value ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Big Pharma Split Corp Class A Capital Reinvestment Ratio (2020–2023)
This chart tracks Big Pharma Split Corp Class A's Capital Reinvestment Ratio across 2 annual periods. For the full cash flow conversion analysis, see PRM operating cash flow.
Annual Capital Reinvestment Ratio for Big Pharma Split Corp Class A (2020–2023)
Year-by-year Capital Reinvestment Ratio for Big Pharma Split Corp Class A from 2020 to 2023. See how much free cash does Big Pharma Split Corp Class A generate to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (CAD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2023 | 0.00x | CA$11.86 Million | CA$3.00 | ▼ -63.3% |
| 2020 | 0.00x | CA$4.35 Million | CA$3.00 | — |